|
Iloperidone Sublicense to Novartis Pharma AG (Details Textual) (USD $)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
May 31, 2001
Novartis [Member]
|
Dec. 31, 2012
Novartis [Member]
|
|
| Iloperidone Sublicense to Novartis Pharma AG (Textual) [Abstract] | |||||
| License revenue, recognized | $ 2,325,000 | $ 0 | $ 24,000 | $ 2,500,000 | |
| Percentage of first annual sales for calculating net royalty up to $200M | 8.00% | ||||
| Percentage of next slab of annual sales for calculating net royalty | 10.00% | ||||
| Threshold for calculating second tier royalties (i.e. 10% royalty on net sales > $200M ) | $ 200,000,000 | ||||
| X | ||||||||||
|
- Definition
Amount of annual sales for calculating royalty payment. No definition available.
|
| X | ||||||||||
|
- Definition
Percentage of first annual sales for calculating net royalty. No definition available.
|
| X | ||||||||||
|
- Definition
Percentage of next slab of annual sales for calculating net royalty. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|